Company
United StatesThrombolysis in Myocardial Infarction (TIMI) Study Group, Boston, MA – FDA Inspections
Inspection records and compliance data for Thrombolysis in Myocardial Infarction (TIMI) Study Group in Boston, Massachusetts. 2 FDA inspections on record, last inspected October 12, 2017.
Company Profile
This profile covers Thrombolysis in Myocardial Infarction (TIMI) Study Group based in Boston, Massachusetts, United States.
FDA Inspection History
- FDA inspections
- 2
- OAI
- 0
- VAI
- 0
- NAI
- 2
- Form 483s
- 0
- Warning letters
- 0
First inspected August 25, 2015. Last inspected October 12, 2017.
FDA inspections (2)
| Date | Result | FDA center(s) | Insp. # |
|---|---|---|---|
| October 12, 2017 | NAI | Human Drugs · Bioresearch Monitoring | 1029812 |
| August 25, 2015 | NAI | Human Drugs · Bioresearch Monitoring | 945856 |
FDA documents
No Form 483s, Warning Letters or EIRs on record.
Related Companies (10)
Companies with similar regulatory profiles, compliance history, and operations.
Company Information
Name
Thrombolysis in Myocardial Infarction (TIMI) Study Group
FEI Number
3011640710
Address
350 Longwood Ave Fl 1, Boston, Massachusetts 02115, United States
Country
United States
ID: ccef5643-4dd8-495d-b5ca-736dd6e91f62